The multi-functional role of sphingosylphosphorylcholine

Graeme F. Nixon (Corresponding Author), Fiona A. Mathieson, Irene Hunter

Research output: Contribution to journalLiterature review

57 Citations (Scopus)
3 Downloads (Pure)

Abstract

The sphingomyelin metabolite, sphingosylphosphorylcholinc (SPC) has been the subject of much recent interest and controversy. Studies have indicated that SPC naturally occurs in plasma and a constituent of lipoproteins. Synthesis is also increased in some pathological conditions. Research has demonstrated that SPC is a potentially important lipid mediator of cell type specific functions in major tissues, such as heart, blood vessels, skin, brain and immune system. These effects are regulated via a number of different intracellular signalling cascades, also dependent upon cell type. Initial reports identifying high affinity SPC receptors at first appeared to reinforce the physiological relevance of this sphingolipid. However, these studies have now been retracted. Some SPC effects have been shown be occur via plasma membrane receptors for the related sphingolipid, sphingosine I-phosphate (SIP). Despite a lack of well-defined receptor signal transduction mechanisms and sparse pharmacological data, several key characteristics of SPC are now emerging. SPC can act as a mitogen in several different cell types and in certain circumstances, may also be a pro-inflammatory mediator. In this review, these actions of SPC are discussed with a view to understanding the potential physiological relevance of this sphingolipid. (c) 2007 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)62-75
Number of pages14
JournalProgress in Lipid Research
Volume47
DOIs
Publication statusPublished - 2008

Keywords

  • sphingosylphosphorylcholine
  • sphingosine 1-phosphate
  • cardiovascular
  • inflammation
  • epidermis
  • calcium
  • protein-coupled receptor
  • vascular smooth-muscle
  • sphingosine 1-phosphate receptor
  • mesenchymal stem-cells
  • niemann-pick-disease
  • lipoprotein-associated lysosphingolipids
  • intercellular-adhesion molecule-1
  • phospholipase-c activation
  • human dermal fibroblasts
  • human endothelial-cells

Cite this

The multi-functional role of sphingosylphosphorylcholine. / Nixon, Graeme F. (Corresponding Author); Mathieson, Fiona A.; Hunter, Irene.

In: Progress in Lipid Research, Vol. 47, 2008, p. 62-75.

Research output: Contribution to journalLiterature review

Nixon, Graeme F. ; Mathieson, Fiona A. ; Hunter, Irene. / The multi-functional role of sphingosylphosphorylcholine. In: Progress in Lipid Research. 2008 ; Vol. 47. pp. 62-75.
@article{b5230e9b3df1461586a1809735af8d56,
title = "The multi-functional role of sphingosylphosphorylcholine",
abstract = "The sphingomyelin metabolite, sphingosylphosphorylcholinc (SPC) has been the subject of much recent interest and controversy. Studies have indicated that SPC naturally occurs in plasma and a constituent of lipoproteins. Synthesis is also increased in some pathological conditions. Research has demonstrated that SPC is a potentially important lipid mediator of cell type specific functions in major tissues, such as heart, blood vessels, skin, brain and immune system. These effects are regulated via a number of different intracellular signalling cascades, also dependent upon cell type. Initial reports identifying high affinity SPC receptors at first appeared to reinforce the physiological relevance of this sphingolipid. However, these studies have now been retracted. Some SPC effects have been shown be occur via plasma membrane receptors for the related sphingolipid, sphingosine I-phosphate (SIP). Despite a lack of well-defined receptor signal transduction mechanisms and sparse pharmacological data, several key characteristics of SPC are now emerging. SPC can act as a mitogen in several different cell types and in certain circumstances, may also be a pro-inflammatory mediator. In this review, these actions of SPC are discussed with a view to understanding the potential physiological relevance of this sphingolipid. (c) 2007 Elsevier Ltd. All rights reserved.",
keywords = "sphingosylphosphorylcholine, sphingosine 1-phosphate, cardiovascular, inflammation, epidermis, calcium, protein-coupled receptor, vascular smooth-muscle, sphingosine 1-phosphate receptor, mesenchymal stem-cells, niemann-pick-disease, lipoprotein-associated lysosphingolipids, intercellular-adhesion molecule-1, phospholipase-c activation, human dermal fibroblasts, human endothelial-cells",
author = "Nixon, {Graeme F.} and Mathieson, {Fiona A.} and Irene Hunter",
year = "2008",
doi = "10.1016/j.plipres.2007.11.001",
language = "English",
volume = "47",
pages = "62--75",
journal = "Progress in Lipid Research",
issn = "0163-7827",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - The multi-functional role of sphingosylphosphorylcholine

AU - Nixon, Graeme F.

AU - Mathieson, Fiona A.

AU - Hunter, Irene

PY - 2008

Y1 - 2008

N2 - The sphingomyelin metabolite, sphingosylphosphorylcholinc (SPC) has been the subject of much recent interest and controversy. Studies have indicated that SPC naturally occurs in plasma and a constituent of lipoproteins. Synthesis is also increased in some pathological conditions. Research has demonstrated that SPC is a potentially important lipid mediator of cell type specific functions in major tissues, such as heart, blood vessels, skin, brain and immune system. These effects are regulated via a number of different intracellular signalling cascades, also dependent upon cell type. Initial reports identifying high affinity SPC receptors at first appeared to reinforce the physiological relevance of this sphingolipid. However, these studies have now been retracted. Some SPC effects have been shown be occur via plasma membrane receptors for the related sphingolipid, sphingosine I-phosphate (SIP). Despite a lack of well-defined receptor signal transduction mechanisms and sparse pharmacological data, several key characteristics of SPC are now emerging. SPC can act as a mitogen in several different cell types and in certain circumstances, may also be a pro-inflammatory mediator. In this review, these actions of SPC are discussed with a view to understanding the potential physiological relevance of this sphingolipid. (c) 2007 Elsevier Ltd. All rights reserved.

AB - The sphingomyelin metabolite, sphingosylphosphorylcholinc (SPC) has been the subject of much recent interest and controversy. Studies have indicated that SPC naturally occurs in plasma and a constituent of lipoproteins. Synthesis is also increased in some pathological conditions. Research has demonstrated that SPC is a potentially important lipid mediator of cell type specific functions in major tissues, such as heart, blood vessels, skin, brain and immune system. These effects are regulated via a number of different intracellular signalling cascades, also dependent upon cell type. Initial reports identifying high affinity SPC receptors at first appeared to reinforce the physiological relevance of this sphingolipid. However, these studies have now been retracted. Some SPC effects have been shown be occur via plasma membrane receptors for the related sphingolipid, sphingosine I-phosphate (SIP). Despite a lack of well-defined receptor signal transduction mechanisms and sparse pharmacological data, several key characteristics of SPC are now emerging. SPC can act as a mitogen in several different cell types and in certain circumstances, may also be a pro-inflammatory mediator. In this review, these actions of SPC are discussed with a view to understanding the potential physiological relevance of this sphingolipid. (c) 2007 Elsevier Ltd. All rights reserved.

KW - sphingosylphosphorylcholine

KW - sphingosine 1-phosphate

KW - cardiovascular

KW - inflammation

KW - epidermis

KW - calcium

KW - protein-coupled receptor

KW - vascular smooth-muscle

KW - sphingosine 1-phosphate receptor

KW - mesenchymal stem-cells

KW - niemann-pick-disease

KW - lipoprotein-associated lysosphingolipids

KW - intercellular-adhesion molecule-1

KW - phospholipase-c activation

KW - human dermal fibroblasts

KW - human endothelial-cells

U2 - 10.1016/j.plipres.2007.11.001

DO - 10.1016/j.plipres.2007.11.001

M3 - Literature review

VL - 47

SP - 62

EP - 75

JO - Progress in Lipid Research

JF - Progress in Lipid Research

SN - 0163-7827

ER -